ARTICLE | Product Development
PG boost
May 23, 2005 7:00 AM UTC
Two recent events illustrate that clinical applications for genomics-based compounds and the use of biomarkers will be more complex than many suppose, and could just as easily lead to wider markets for drugs as to narrower ones.
deCode Genetics Inc. broadened its strategy for development of its DG031 FLAP inhibitor to prevent myocardial infarction (MI) after Phase IIa data showed that the product could be useful in a wider patient population than originally expected. ...